Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Page 1
Cost-effectiveness of Mechanical Thrombectomy More Than 6 Hours After Symptom Onset Among Patients With Acute Ischemic Stroke.
Peultier AC, Pandya A, Sharma R, Severens JL, Redekop WK. Peultier AC, et al. Among authors: severens jl. JAMA Netw Open. 2020 Aug 3;3(8):e2012476. doi: 10.1001/jamanetworkopen.2020.12476. JAMA Netw Open. 2020. PMID: 32840620 Free PMC article.
Health-economic evidence is needed to determine whether the short-term health benefits of late MT translate to a cost-effective option during a lifetime in the United States. ...
Health-economic evidence is needed to determine whether the short-term health benefits of late MT translate to a cost-effective optio …
Added Prognostic Value of Cerebrospinal Fluid Biomarkers in Predicting Decline in Memory Clinic Patients in a Prospective Cohort.
Handels RL, Joore MA, Vos SJ, Aalten P, Ramakers IH, Rikkert MO, Scheltens P, Jansen WJ, Visser PJ, van Berckel BM, van Domburg P, Smid M, Hoff E, Hoogmoed J, Bouwman F, Claassen J, Leentjens AF, Wolfs CA, Severens JL, Verhey FR. Handels RL, et al. Among authors: severens jl. J Alzheimers Dis. 2016 Mar 31;52(3):875-85. doi: 10.3233/JAD-151120. J Alzheimers Dis. 2016. PMID: 27031483
BACKGROUND: Limited information is available on short-term prognosis of Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (CSF) in addition to routine diagnostic workup. ...This suggests that the standard diagnostic workup without CSF biomarkers allows fairly accu …
BACKGROUND: Limited information is available on short-term prognosis of Alzheimer's disease (AD) biomarkers in cerebrospinal fluid (C …
Treatment variation in stent choice in patients with stable or unstable coronary artery disease.
Burgers LT, McClellan EA, Hoefer IE, Pasterkamp G, Jukema JW, Horsman S, Pijls NH, Waltenberger J, Hillaert MA, Stubbs AC, Severens JL, Redekop WK. Burgers LT, et al. Among authors: severens jl. Neth Heart J. 2016 Feb;24(2):110-9. doi: 10.1007/s12471-015-0783-5. Neth Heart J. 2016. PMID: 26762359 Free PMC article.
The choice of treatment is considered important since it could lead to differences in long-term outcomes. This study explores the associations with stent choice: i.e. drug-eluting stent (DES) versus bare-metal stents (BMS) for Dutch patients diagnosed with stable or unstab …
The choice of treatment is considered important since it could lead to differences in long-term outcomes. This study explores the ass …
Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Blommestein HM, Armstrong N, Ryder S, Deshpande S, Worthy G, Noake C, Riemsma R, Kleijnen J, Severens JL, Al MJ. Blommestein HM, et al. Among authors: severens jl. Pharmacoeconomics. 2016 Jan;34(1):23-31. doi: 10.1007/s40273-015-0318-3. Pharmacoeconomics. 2016. PMID: 26314282 Free PMC article.
The option of dose adjustments after 16 weeks due to dose-limiting toxicities or lack of response made long-term effectiveness estimates unreliable, e.g. overall survival (OS). ...
The option of dose adjustments after 16 weeks due to dose-limiting toxicities or lack of response made long-term effectiveness estima …
Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis.
Tran-Duy A, Boonen A, Kievit W, van Riel PL, van de Laar MA, Severens JL. Tran-Duy A, et al. Among authors: severens jl. Pharmacoeconomics. 2014 Oct;32(10):1015-28. doi: 10.1007/s40273-014-0184-4. Pharmacoeconomics. 2014. PMID: 24972589
OBJECTIVE: This study aimed at developing a model that could simulate long-term patient outcomes and cost effectiveness of treatment strategies with and without inclusion of BRMs following a clinical guideline for treatment decisions. ...Treatment effect on disease activit …
OBJECTIVE: This study aimed at developing a model that could simulate long-term patient outcomes and cost effectiveness of treatment …
The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension.
van Gestel A, Schouten JS, Beckers HJ, Severens JL, Hendrikse F, Webers CA. van Gestel A, et al. Among authors: severens jl. Acta Ophthalmol. 2014 Sep;92(6):513-23. doi: 10.1111/aos.12328. Epub 2013 Dec 16. Acta Ophthalmol. 2014. PMID: 24330516 Free article.
PURPOSE: To investigate the long-term health and economic consequences of direct treatment initiation in ocular hypertension patients. ...
PURPOSE: To investigate the long-term health and economic consequences of direct treatment initiation in ocular hypertension patients …
Natural progression model of cognition and physical functioning among people with mild cognitive impairment and alzheimer's disease.
Handels RL, Xu W, Rizzuto D, Caracciolo B, Wang R, Winblad B, Verhey FR, Severens JL, Fratiglioni L, Joore MA, Wimo A. Handels RL, et al. Among authors: severens jl. J Alzheimers Dis. 2013;37(2):357-65. doi: 10.3233/JAD-130296. J Alzheimers Dis. 2013. PMID: 23948894
Both cognitive and physical function may decline gradually after AD onset. The empirical models can be used to evaluate long-term disease progression of new interventions for AD....
Both cognitive and physical function may decline gradually after AD onset. The empirical models can be used to evaluate long-term dis …
Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M. Garrison LP Jr, et al. Among authors: severens jl. Value Health. 2013 Jul-Aug;16(5):703-19. doi: 10.1016/j.jval.2013.04.011. Epub 2013 Jul 19. Value Health. 2013. PMID: 23947963 Free article.
The ex post evaluation of a PBRSA should, however, be a multidimensional exercise that assesses many aspects, including not only the impact on long-term cost-effectiveness and whether appropriate evidence was generated but also process indicators, such as whether and how t …
The ex post evaluation of a PBRSA should, however, be a multidimensional exercise that assesses many aspects, including not only the impact …
Diagnostic and economic evaluation of new biomarkers for Alzheimer's disease: the research protocol of a prospective cohort study.
Handels RL, Aalten P, Wolfs CA, OldeRikkert M, Scheltens P, Visser PJ, Joore MA, Severens JL, Verhey FR. Handels RL, et al. Among authors: severens jl. BMC Neurol. 2012 Aug 10;12:72. doi: 10.1186/1471-2377-12-72. BMC Neurol. 2012. PMID: 22883691 Free PMC article. Clinical Trial.
The research goals are to 1) assess the diagnostic test accuracy of current clinical diagnostic work-up and emerging biomarkers in MRI, PET and CSF, 2) perform a cost-consequence analysis and 3) assess long-term cost-effectiveness by an economic model. METHODS/DESIGN: In a …
The research goals are to 1) assess the diagnostic test accuracy of current clinical diagnostic work-up and emerging biomarkers in MRI, PET …
The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma.
van Gestel A, Webers CA, Severens JL, Beckers HJ, Jansonius NM, Hendrikse F, Schouten JS. van Gestel A, et al. Among authors: severens jl. Acta Ophthalmol. 2012 Feb;90(1):20-31. doi: 10.1111/j.1755-3768.2011.02318.x. Acta Ophthalmol. 2012. PMID: 22289192 Free article.
PURPOSE: To evaluate the long-term effects and costs of four treatment strategies for primary open-angle glaucoma compared to usual care. ...
PURPOSE: To evaluate the long-term effects and costs of four treatment strategies for primary open-angle glaucoma compared to usual c …
27 results